Important: New Login Process

We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.

  • If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
  • If you log in with a username and password, you will be prompted to set a new password before accessing your account.

Go to the Login Page to get started.

We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.

BioCentury
  • Company Profiles
  • Target Profiles
  • Product Profiles
Explore BCIQ profiles by entering a target name.
BioCentury | Feb 26, 2025
Distillery Therapeutics

Inhibiting DUSP6 for colorectal cancer

BioCentury | Apr 20, 2024
Product Development

Triple-negative breast cancer attracts target innovation at AACR 

BioCentury identifies 44 new targets presented at meeting
BioCentury | Dec 3, 2021
Discovery & Translation

Mapping the plasma proteome to identify drug targets; plus GSK-Vir, Codiak and more

BioCentury’s roundup of translational news
BioCentury | Sep 10, 2021
Targets & Mechanisms

Integrated stress response key to seemingly disparate diseases?

A flurry of preclinical studies builds the case for the integrated stress response as a central driver of many diseases
BioCentury | May 23, 2018
Distillery Therapeutics

Transplant

BioCentury | May 17, 2018
Preclinical News

Targeting DOT1L, DUSP6 to prevent GvHD

BioCentury | Jan 25, 2017
Distillery Therapeutics

Endocrine / Metabolic

BioCentury | Jan 13, 2017
Targets & Mechanisms

Gut control

Three new avenues for using the microbiome to treat obesity
BioCentury | Jul 16, 2015
Distillery Therapeutics

Therapeutics: Dual specificity phosphatase 6 (DUSP6; MKP3)

Items per page:
1 - 10 of 11